Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum
Status: Enrolling
Updated:  7/13/2015
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum
Status: Enrolling
Updated: 7/13/2015
Medical X-Ray Center, PC
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum
Status: Enrolling
Updated:  7/13/2015
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum
Status: Enrolling
Updated: 7/13/2015
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum
Status: Enrolling
Updated:  7/13/2015
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum
Status: Enrolling
Updated: 7/13/2015
Fredericksburg Oncology, Incorporated
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum
Status: Enrolling
Updated:  7/13/2015
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum
Status: Enrolling
Updated: 7/13/2015
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum
Status: Enrolling
Updated:  7/13/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum
Status: Enrolling
Updated: 7/13/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum
Status: Enrolling
Updated:  7/13/2015
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum
Status: Enrolling
Updated: 7/13/2015
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum
Status: Enrolling
Updated:  7/13/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum
Status: Enrolling
Updated: 7/13/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum
Status: Enrolling
Updated:  7/13/2015
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum
Status: Enrolling
Updated: 7/13/2015
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum
Status: Enrolling
Updated:  7/13/2015
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum
Status: Enrolling
Updated: 7/13/2015
Green Bay Oncology, Limited - Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum
Status: Enrolling
Updated:  7/13/2015
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer
A Phase II Study Of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin (CF), and Cetuximab (C225) For Patients With Unresectable Hepatic Metastases From Metastatic Adenocarcinoma Of The Colon Or Rectum
Status: Enrolling
Updated: 7/13/2015
Green Bay Oncology, Limited - Sturgeon Bay
mi
from
Sturgeon Bay, WI
Click here to add this to my saved trials
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated:  7/14/2015
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated: 7/14/2015
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated:  7/14/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated: 7/14/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated:  7/14/2015
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated: 7/14/2015
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated:  7/14/2015
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated: 7/14/2015
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated:  7/14/2015
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated: 7/14/2015
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Click here to add this to my saved trials
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated:  7/14/2015
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated: 7/14/2015
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated:  7/14/2015
CentraCare Clinic
mi
from
Saint Cloud, MN
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated: 7/14/2015
CentraCare Clinic
mi
from
Saint Cloud, MN
Click here to add this to my saved trials
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated:  7/14/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated: 7/14/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated:  7/14/2015
Medcenter One Health System
mi
from
Bismarck, ND
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated: 7/14/2015
Medcenter One Health System
mi
from
Bismarck, ND
Click here to add this to my saved trials
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated:  7/14/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated: 7/14/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated:  7/14/2015
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated: 7/14/2015
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated:  7/14/2015
Allan Blair Cancer Centre
mi
from
Regina,
Genetic Study of Patients and Families With a History of Colorectal Cancer
The Familial Colorectal Neoplasia Collaborative Group
Status: Enrolling
Updated: 7/14/2015
Allan Blair Cancer Centre
mi
from
Regina,
Click here to add this to my saved trials
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated:  7/14/2015
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated: 7/14/2015
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated:  7/14/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated: 7/14/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated:  7/14/2015
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated: 7/14/2015
CCOP - Cedar Rapids Oncology Project
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated:  7/14/2015
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated: 7/14/2015
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated:  7/14/2015
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated: 7/14/2015
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Click here to add this to my saved trials
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated:  7/14/2015
CCOP - Wichita
mi
from
Wichita, KA
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated: 7/14/2015
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated:  7/14/2015
CCOP - Ochsner
mi
from
New Orleans, LA
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated: 7/14/2015
CCOP - Ochsner
mi
from
New Orleans, LA
Click here to add this to my saved trials
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated:  7/14/2015
CCOP - Duluth
mi
from
Duluth, MN
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated: 7/14/2015
CCOP - Duluth
mi
from
Duluth, MN
Click here to add this to my saved trials
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated:  7/14/2015
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated: 7/14/2015
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated:  7/14/2015
CentraCare Clinic
mi
from
Saint Cloud, MN
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated: 7/14/2015
CentraCare Clinic
mi
from
Saint Cloud, MN
Click here to add this to my saved trials
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated:  7/14/2015
CCOP - Metro-Minnesota
mi
from
Saint Louis Park, MN
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated: 7/14/2015
CCOP - Metro-Minnesota
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated:  7/14/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated: 7/14/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated:  7/14/2015
Medcenter One Health System
mi
from
Bismarck, ND
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated: 7/14/2015
Medcenter One Health System
mi
from
Bismarck, ND
Click here to add this to my saved trials
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated:  7/14/2015
Altru Health Systems
mi
from
Grand Forks, ND
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated: 7/14/2015
Altru Health Systems
mi
from
Grand Forks, ND
Click here to add this to my saved trials
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated:  7/14/2015
CCOP - Geisinger Clinic and Medical Center
mi
from
Danville, PA
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated: 7/14/2015
CCOP - Geisinger Clinic and Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated:  7/14/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated: 7/14/2015
Rapid City Regional Hospital
mi
from
Rapid City, SD
Click here to add this to my saved trials
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated:  7/14/2015
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated: 7/14/2015
CCOP - Sioux Community Cancer Consortium
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated:  7/14/2015
Allan Blair Cancer Centre
mi
from
Regina,
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
Phase I Study of Oral Capecitabine (Xeloda) as a Radiation Enhancer in Locally Unresectable, Residual, or Recurrent Colorectal Cancer Localized in the Pelvis
Status: Enrolling
Updated: 7/14/2015
Allan Blair Cancer Centre
mi
from
Regina,
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
CCOP - Scottsdale Oncology Program
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
CCOP - Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
CCOP - Iowa Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
Siouxland Hematology-Oncology
mi
from
Sioux City, IA
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
CCOP - Wichita
mi
from
Wichita, KA
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
Medcenter One Health System
mi
from
Bismarck, ND
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
Medcenter One Health System
mi
from
Bismarck, ND
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
Altru Health Systems
mi
from
Grand Forks, ND
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
Altru Health Systems
mi
from
Grand Forks, ND
Click here to add this to my saved trials
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated:  7/14/2015
CCOP - Toledo Community Hospital Oncology Program
mi
from
Toledo, OH
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment
Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer
Status: Enrolling
Updated: 7/14/2015
CCOP - Toledo Community Hospital Oncology Program
mi
from
Toledo, OH
Click here to add this to my saved trials